HNGE

Resmed RMD is set to release fourth-quarter fiscal 2026 results on Aug. 6, after the closing bell. The renowned sleep health device maker posted adjusted earnings per share (EPS) of $2.86 in the last reported quarter, surpassing the Zacks Consensus Estimate by 2.51%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.26%. The Zacks Consensus Estimate for revenues is pegged at $1.46 billion, indicating an increase of 8.4% from the year-ago reported figure. The Zacks Consensus Estimate for EPS suggests a 13.7% rise to $2.90. Estimates for earnings have remained stable over the past 60 days. Here’s a brief review of the company’s performance leading up to the announcement. Sleep and Breathing Health Within this segment, Resmed is likely to have benefited from strong demand for its mask portfolio across the United States, Canada and Latin America. Growth might have also accelerated in Europe, Asia and the rest of the world region. Mask and other sales are expected to have witnessed continued growth in resupply and new patient setups, while the VirtuOx acquisition must have contributed to incremental revenues. The company is strategically expanding its mask portfolio with product innovations like AirTouch N30i, F30i Comfort and F30iClear, among others, which should have supported revenues in the fiscal fourth quarter. Device sales numbers are likely to reflect the ongoing combined availability of Resmed’s AirSense 10 and AirSense 11 sleep devices, supporting underlying global demand. The company is also expected to have introduced AirSense 11 to additional countries following regulatory clearances. Resmed’s use of ML, AI and generative AI technology in its digital health products might have positively impacted its overall top line. The company must have also gained from the widespread U.S. adoption of NightOwl, its fingertip-sized home sleep apnea test. In June, Resmed completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders. The acquisition expands Resmed’s clinical sleep health portfolio for the treatment of Restless Legs Syndrome (RLS). We expect this acquisition to have had a positive impact on the quarterly top line. The Zacks Consensus Estimate for Sleep and Breathing Health revenues implies an 8....

AMD stock keeps its latest pullback contained compared with many other chip stocks as its second-quarter earnings report looms large.

Bio-Techne Corporation TECH is expected to release fourth-quarter fiscal 2026 results on Aug. 5. The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 53 cents in the last reported quarter, missing the Zacks Consensus Estimate by 3.64%. The company’s earnings beat estimates in two of the trailing four quarters, matched once and missed in the other, the average surprise being 2.34%. The Zacks Consensus Estimate for revenues is pegged at $317.2 million, indicating an increase of 0.1% from the year-ago reported figure. The consensus estimate for EPS is pinned at 52 cents, implying a decrease of 1.9% from the year-ago reported figure. Estimates for earnings have remained constant at 52 cents per share in the past 30 days. Let’s briefly review the company’s performance leading up to the announcement. In June 2026, Merck KGaA, Darmstadt, Germany, a leading science and technology company, entered into a definitive agreement to acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The proposed transaction has been approved by Bio-Techne's board of directors and the relevant corporate bodies of Merck KGaA, Darmstadt, Germany, and is expected to be closed by late 2026 or early 2027, subject to satisfaction of customary closing conditions. Protein Sciences The company’s core portfolio of research-use-only proteomic agents, featuring more than 6,000 proteins and 400,000 antibody types, declined at a mid-single-digit rate in the previous quarter. However, as the normalization of funding conditions in academia and recent improvements in biotech funding translated into customer spending, this core portfolio might have returned to growth in the to-be-reported quarter. Aside from the two largest cell therapy customers (who temporarily reduced purchases), GMP reagents are likely to have witnessed strong growth, underscoring the strength of its offering and improving end-market demand. In the fiscal fourth quarter, the protein analytical instrumentation business might have continued to demonstrate strong momentum, driven by the Ella benchtop immunoassay platform. Bio-Techne is also expected to have experienced continued traction across the biologic characterization portfolio led by the Maurice platform during the to-be-reported quarter. The Wilson Wolf business must have stood out...

The market expects Carlsmed, Inc. (CARL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 5. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This company is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of +72.8%. Revenues are expected to be $18.52 million, up 53.3% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP read...

Hinge Health Inc. (HNGE) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This company is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -11.9%. Revenues are expected to be $200.51 million, up 44.2% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 4.41% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for p...

STERIS plc STE is scheduled to release first-quarter fiscal 2027 results on Aug. 6, after market close. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.83, which missed the Zacks Consensus Estimate by 1.05%. STE’s earnings beat estimates in two of the trailing four quarters, met once and missed in the other, delivering an average surprise of 0.90%. The Zacks Consensus Estimate for revenues is pegged at $1.51 billion, implying an increase of 8.2% from the year-ago reported figure. The consensus mark for EPS is pegged at $2.54, indicating a year-over-year increase of 8.6%. Estimates for earnings have remained constant at $2.54 per share in the past 30 days. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Healthcare In the previous quarter, growth across all categories was robust. We expect this trend to have continued in the fiscal first quarter as well. The company maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fiscal first-quarter results. Also, capital equipment growth is expected to have remained robust. STERIS completed two tuck-in acquisitions to strengthen its Healthcare portfolio and expand its global reach. The company vertically integrated its MEDglas wall supplier, extending this business into international markets. It acquired a family of gastrointestinal (GI) products, broadening its product portfolio and enhancing its distribution channels. Management expects these two acquisitions to contribute a combined $45 million in revenues during fiscal 2027. The Zacks Consensus Estimate for the segment’s revenues implies an improvement of 9% from the year-ago reported figure. Applied Sterilization Technologies (“AST”) In the fiscal first quarter, Steris is expected to have experienced organic revenue growth within this segment. With over $1 billion in revenues in fiscal 2026, AST crossed a new milestone, exceeding $500 million in operating profit. We expect this momentum to have persisted in the to-be-reported quarter as well. The Zacks Consensus Estimate for the segment’s revenues calls for an increase of 5.6% year over year. STERIS plc price-eps-surprise | STERIS plc Quote Life Sciences The segment's fiscal fourth-quarter 2025 revenues rose year over year due to strong growth in consumables revenues. Th...

IDEXX Laboratories, Inc. IDXX is set to release second-quarter 2026 results on Aug. 4, before the opening bell. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $3.47, which surpassed the Zacks Consensus Estimate by 1.46%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.13%. The Zacks Consensus Estimate for second-quarter revenues is pegged at $1.20 billion, indicating an increase of 8.3% from the year-ago figure. The Zacks Consensus Estimate for EPS is pinned at $3.95, implying a rise of 8.8% from the year-ago figure. Estimates for second-quarter earnings have remained unchanged in the past 30 days. Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to the announcement. Companion Animal Group (“CAG”) The business is likely to have sustained its momentum in the second quarter of 2026, supported by continued volume growth and average global net price improvement. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions. IDEXX VetLab consumables might have benefited from volume expansion driven by net new customer gains in the premium instrument installed base and expanded testing utilization. CAG's premium instrument placements grew 12% year over year in the previous quarter, supported by more than 1,000 new and competitive catalyst placements globally, reflecting strong customer adoption. We expect this momentum to have continued in the second quarter as well. Global Reference Lab revenues are likely to have improved in the second quarter, supported by an expanding customer base and sustained momentum from innovative offerings, such as IDEXX Cancer Dx. Within Veterinary Software, Services and Diagnostic Imaging Systems, recurring revenue growth was likely supported by continued momentum in its vertical SaaS strategy, driven by expanding cloud-based PIMS recurring revenues and increased adoption of the newly launched DR50 Plus platform. On the flip side, ongoing macroeconomic and sector headwinds must have continued to restrict the full extent of CAG Diagnostics’ growth. Also, Rapid Assay results might have remained a drag, with the ongoing customer migration of pancreatic lipase testing to the Catalyst instrument platform. The Zacks...

Omnicell OMCL is set to release second-quarter 2026 results on July 30, before market open. In the last reported quarter, the company posted adjusted earnings per share (EPS) of 55 cents, which surpassed the Zacks Consensus Estimate by 66.67%. Omnicell beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 34.65%. The Zacks Consensus Estimate for revenues is pegged at $309.6 million, which suggests 6.6% growth from the year-ago reported figure. The Zacks Consensus Estimate for earnings is pinned at 48 cents per share, which implies a 6.7% rise from the year-ago recorded actuals. Estimates for second-quarter earnings have remained unchanged at 48 cents per share in the past 30 days. Here’s a brief overview of the company’s performance leading up to this announcement. The company is expected to have delivered another quarter of solid growth, supported by continued execution of its Connected Devices strategy and expanding recurring revenue streams. Demand is likely to have remained strong across inpatient and outpatient pharmacies as well as broader patient care settings, reflecting continued adoption of Omnicell's medication management solutions. Second-quarter revenue growth is also expected to have been supported by increasing penetration of OmniSphere, a cloud-native medication management platform, as healthcare providers continue to prioritize enterprise-wide automation, workflow optimization and data-driven medication management. The second-quarter top line is also likely to have benefited from continued customer wins among large and complex health systems. The recently launched Titan XT next-generation automated dispensing system is expected to have gained further commercial traction, supported by its integration with the OmniSphere platform. The combined offering is likely to have strengthened Omnicell's value proposition by providing enterprise-wide visibility, guided clinical workflows and a modern cloud-based infrastructure designed for large healthcare organizations. From a segment perspective, Product revenues are expected to have benefited from sustained demand for the Connected Devices portfolio across both North America and international markets, supported by ongoing capital investments from healthcare providers. The Zacks Consensus Estimate for Product revenues indicates 5.2% year-over-yea...

Align Technology, Inc. ALGN is set to release second-quarter 2026 results on July 29, after the closing bell. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.58, which surpassed the Zacks Consensus Estimate by 14.16%. Align Technology beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 7.80%. The Zacks Consensus Estimate for revenues is pegged at $1.05 billion, which suggests 3.9% growth from the year-ago reported figure. The Zacks Consensus Estimate for earnings is pinned at $2.56 per share, which implies a 2.8% rise from the year-ago recorded actuals. Estimates for second-quarter earnings have remained unchanged at $2.56 per share in the past 30 days. Here’s a brief overview of the company’s performance leading up to this announcement. Clear Aligner The segment is likely to have benefited from higher Clear Aligner volumes, with particular strength across the EMEA, APAC and Latin America, with continued stability in North America. Both orthodontists and GP dentist channels may have seen volume growth, driven by growth across adults, teens and growing kids. From a product standpoint, it is likely to have seen strong contributions from Invisalign First and the Invisalign Palatal Expander with Mandibular Advancement with Occlusal Blocks. Dental and orthodontic service organizations (DSOs) must have remained a key, scalable growth channel in the to-be-reported quarter, with continued strong progress across all major regions. Meanwhile, the doctor subscription program (DSP), which includes retention, touch-up and relapse cases, is expected to have maintained strong momentum during the quarter. The Zacks Consensus Estimate for Clear Aligner revenues indicates 6.3% year-over-year growth. Align Technology, Inc. price-eps-surprise | Align Technology, Inc. Quote Imaging Systems & CAD/CAM Services (Systems and Services) Within this segment, revenues are likely to have benefited from higher volumes across all regions and continued adoption of iTero Lumina scanner. In the first quarter, the total installed base of active scanners exceeded 125,000 globally. We expect this trend to have continued in the to-be-reported quarter as well. exocad achieved strong revenue growth, reinforcing the company’s strategy to integrate orthodontics and restorative dentistry within a custom...

Quest Diagnostics DGX is set to release second-quarter 2026 results on July 23, before the market opens. In the last reported quarter, the renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.50, which surpassed the Zacks Consensus Estimate by 5.49%. The company beat on earnings in each of the trailing four quarters, the average surprise being 3.50%. The Zacks Consensus Estimate for revenues is pegged at $2.98 billion, indicating an increase of 7.9% from the year-ago reported figure. The Zacks Consensus Estimate for the company’s EPS suggests a 7.3% rise to $2.81. Estimates for Quest Diagnostics’ Q2 earnings have remained unchanged in the past 30 days. Here’s a brief review of the company’s performance leading up to the announcement. As in the previous quarter, second-quarter 2026 revenues are expected to have been supported by broad-based demand for its clinical innovations, expansion into new clinical areas, and partnerships with leading healthcare and consumer health organizations. In the physician channel, a key driver has likely been geographic expansion from greater health plan access, expanding the reach of Quest Diagnostics’ lab services. Enterprise accounts might have contributed additional revenues from new customer wins and expanded business. The company's entry into end-stage renal disease (ESRD), a new clinical area, is expected to have boosted revenues in the to-be-reported quarter. Growth in the hospital channel may have been driven by Co-Lab solutions, which leverages the company’s lab and process management expertise to optimize quality and drive cost efficiencies. Early in 2026, DGX began scaling its Co-Lab solutions across all 21 hospitals of Corewell Health, its largest implementation to date. This is expected to have had a positive impact on revenues. Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote In the consumer channel, as in recent quarters, the company is likely to have generated strong revenue growth from both questhealth.com and its portfolio of leading consumer health collaborations. This growth is expected to have been driven by notable demand for its new solutions such as the Elite health profile and autoimmune and hormone tests. In the second quarter of 2026, the company is likely to have maintained momentum in Advanced Diagnostics, which includes non-routine and...

SAN FRANCISCO, July 06, 2026--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) announced today that it will report its financial results for the quarter ended June 30, 2026, after the U.S. financial markets close on Tuesday, August 4, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health’s vision is to scale and automate the delivery of health care. Leveraging an AI-powered care model, wearable devices and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that improves member outcomes and experiences while reducing costs for clients. The company is headquartered in San Francisco, California. View source version on businesswire.com: https://www.businesswire.com/news/home/20260706251842/en/ Contacts Investor Relations Contact: [email protected] Media Contact: [email protected]

It has been about a month since the last earnings report for Hinge Health Inc. (HNGE). Shares have added about 7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Hinge Health Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Hinge Health Inc. reported adjusted earnings per share of 45 cents in the first quarter of 2026, which beat the Zacks Consensus Estimate of 39 cents by 15.4%. The bottom line decreased 65.3% year over year. GAAP earnings per share for the quarter was 41 cents, reflecting a downtick of 68.7% from the year-ago figure. Hinge Health registered revenues of $182.3 million in the first quarter, up 47% year over year. The increase was primarily driven by the strength of its platform that automates care delivery, improves member outcomes and lowers costs. The figure surpassed the Zacks Consensus Estimate by 5.8%. LTM calculated billings reached $769.9 million, up from $507 million as of March 31, 2025. The company expanded its client base to 2,849, compared with 2,311 clients in the prior-year period. In the first quarter, Hinge Health’s adjusted gross profit rose 54.8% year over year to $155.4 million. The adjusted gross margin expanded 400 basis points (bps) to 85%. Research and development expenses increased 29.1% year over year to $30.3 million, sales and marketing expenses increased 47.3% year over year to $68.8 million, and general and administrative expenses increased 36.4% year over year to $23 million. Total operating expenses of $122.2 million rose 40.3% year over year. Adjusted operating income totaled $46.2 million, up 208.7% year over year. The adjusted operating margin was 25%, up 1300 bps from the prior-year quarter’s figure. Hinge Health exited first-quarter 2026 with cash and cash equivalents of $186.7 million compared with $207.9 million at the end of fourth-quarter 2025. Net cash provided by operating activities at the end of first-quarter 2026 was $43.1 million compared with $4.9 million a year ago. Hinge Health has provided its financial outlook for the second quarter of 2026 and updated its outlook for the full year. For the second quarter, the company expects revenues in the ran...